4 results on '"Chilingirova NP"'
Number of results to display per page
Search Results
2. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth
- Author
-
Konstantinos Kamposioras, Davide Mauri, Konstantinos Papadimitriou, Alan Anthoney, Nadia Hindi, Branka Petricevic, Mario Dambrosio, Antonis Valachis, Pantelis Kountourakis, Jindrich Kopecky, Cvetka Grašič Kuhar, Lazar Popovic, Nataliya P. Chilingirova, George Zarkavelis, Ramon Andrade de Mello, Natalija Dedić Plavetić, Christos Christopoulos, Bianca Mostert, John R. Goffin, Dimitiros Tzachanis, Haytham Hamed Saraireh, Fei Ma, Ida Pavese, Maria Tolia, [Kamposioras,K] Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. [Mauri,D, Zarkavelis,G] Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece. [Papadimitriou,K] Early Clinical Trials Unit, Antwerp University Hospital, Antwerp, Belgium. [Anthoney,A] Leeds Institute of Medical Research at St James' Hospital, University of Leeds, Leeds, United Kingdom. [Hindi,N] Department of Medical Oncology, University Hospital Virgen del Rocío, Sevilla, Spain. [Hindi,N] TERABIS Group, IBiS (Instituto de Biomedicina de Sevilla)/HUVR/CSIC/Universidad de Sevilla), Sevilla, Spain. [Petricevic,B] Medizinische Abteilung, Zentrum für Onkologie und Hämatologie mit Ambulanz und alliativstation Wilhelminenspital, Vienna, Austria. [Dambrosio,M] Department of Clinical Oncology, Clinica San Carlo, Milan, Italy. [Valachis,A] Department of Oncology, Faculty of Medicine & Health, Örebro University, Örebro, Sweden. [Kountourakis,P] Medical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus. [Kopecky,J] Department of Clinical Oncology, University Hospital, Charles University-Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czechia. [Kuhar,CG] Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. [Popovic,L] Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad, Serbia. [Chilingirova,NP] University Specialized Hospital for Active Treatment in Oncology, Medical Oncology Clinic, Sofia, Bulgaria. [Chilingirova,NP] Medical University Pleven, Pleven, Bulgaria. [de Mello,RA] Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil. [de Mello,RA] Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. [Plavetić,ND] University Hospital Centre, Zagreb Department of Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia. [Christopoulos,C] Service de Radiothérapie Oncologique, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France. [Mostert,B] Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. [Goffin,JR] Department of Oncology, McMaster University Juravinski Cancer Centre, Hamilton, ON, Canada. [Tzachanis,D] Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, United States. [Saraireh,HH] Radiation Oncology Department, Jordanian Royal Medical Services, Amman, Jordan. [Ma,F] Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [Pavese,I] Service d'Oncologie, GHT Grand Paris Nord-Est, Montfermeil, France. [Tolia,M] Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Greece., and Medical Oncology
- Subjects
Oncology ,Cancer Research ,Service delivery framework ,Review ,Recommendations ,Disciplines and Occupations::Health Occupations::Medicine::Internal Medicine::Medical Oncology [Medical Subject Headings] ,0302 clinical medicine ,Sociedades médicas ,Epidemiology ,Pandemic ,Medicine ,030212 general & internal medicine ,Directrices para la planificación en salud ,Cancer ,COVID-19 ,oncology ,guidelines ,Instituciones oncológicas ,Chemicals and Drugs::Biological Factors::Antigens::Vaccines, Synthetic [Medical Subject Headings] ,Diseases::Neoplasms [Medical Subject Headings] ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Health Care::Health Services Administration::Organization and Administration::Decision Making, Organizational [Medical Subject Headings] ,Health Care::Health Care Economics and Organizations::Health Planning::Health Planning Guidelines [Medical Subject Headings] ,Infectious Diseases ,Internacionalidad ,030220 oncology & carcinogenesis ,international ,International ,Covid-19 ,medicine.medical_specialty ,Health Care::Environment and Public Health::Public Health::Epidemiologic Measurements::Risk Assessment [Medical Subject Headings] ,Coronavirus disease 2019 (COVID-19) ,Infecciones por coronavirus ,Oncology and Carcinogenesis ,Phenomena and Processes::Physiological Phenomena::Physiological Processes::Adaptation, Physiological [Medical Subject Headings] ,Patient assessment ,lcsh:RC254-282 ,03 medical and health sciences ,societies ,Online search ,Internal medicine ,Effective treatment ,business.industry ,Prevention ,Health Care::Environment and Public Health::Public Health::Disease Outbreaks::Epidemics::Pandemics [Medical Subject Headings] ,Health Care::Health Care Economics and Organizations::Organizations::Societies::Societies, Medical [Medical Subject Headings] ,Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings] ,Good Health and Well Being ,Infectious disease (medical specialty) ,recommendations ,Human medicine ,business ,Societies - Abstract
Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak. Methods: We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies. Results: By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis. Conclusions: In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.
- Published
- 2020
- Full Text
- View/download PDF
3. Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.
- Author
-
Mauri D, Kamposioras K, Matthaios D, Tolia M, Nixon I, Dambrosio M, Zarkavelis G, Papadimitriou K, Petricevic B, Kountourakis P, Kopecky J, Grašič Kuhar C, Popovic L, Chilingirova NP, De Mello RA, Dedić Plavetić N, Katsanos K, Mostert B, Alongi F, de Bari B, Corradini S, Kampletsas E, Gazouli I, Gkoura S, Amylidi AL, and Valachis A
- Subjects
- High-Throughput Nucleotide Sequencing, Humans, Mutation, Oncogenes, Circulating Tumor DNA genetics, Colonic Neoplasms genetics, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology
- Abstract
Background: Management of Ras wild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge., Summary: Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of sophisticated laboratory techniques. The clinical hurdle of re-biopsy and tumor heterogeneity can be overcome by the implementation of next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA) and identify druggable mutations or recovery of RAS-wildness. In this opinion paper, we summarize with critical thinking the clinical approach to be followed after the failure of first-line treatment in Ras wild-type CRC tumors with the use of NGS. Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can by guided by the use of NGS. The use of NGS platforms for serial analysis of ctDNA is an important step to better understand the molecular landscape of metastatic CRC and guide clinical decisions., Key Messages: NGS should be considered a mainstay in clinical practice for the management of CRC patients and health authorities should consider reimbursing its use in the appropriate clinical settings., (© 2022 S. Karger AG, Basel.)
- Published
- 2022
- Full Text
- View/download PDF
4. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth.
- Author
-
Kamposioras K, Mauri D, Papadimitriou K, Anthoney A, Hindi N, Petricevic B, Dambrosio M, Valachis A, Kountourakis P, Kopecky J, Kuhar CG, Popovic L, Chilingirova NP, Zarkavelis G, de Mello RA, Plavetić ND, Christopoulos C, Mostert B, Goffin JR, Tzachanis D, Saraireh HH, Ma F, Pavese I, and Tolia M
- Abstract
Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak., Methods: We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies., Results: By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis., Conclusions: In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally., (Copyright © 2020 Kamposioras, Mauri, Papadimitriou, Anthoney, Hindi, Petricevic, Dambrosio, Valachis, Kountourakis, Kopecky, Kuhar, Popovic, Chilingirova, Zarkavelis, de Mello, Plavetić, Christopoulos, Mostert, Goffin, Tzachanis, Saraireh, Ma, Pavese and Tolia.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.